Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 7 de 7
1.
bioRxiv ; 2024 Mar 16.
Article En | MEDLINE | ID: mdl-38559242

Immunomodulatory imide drugs (IMiDs) including thalidomide, lenalidomide, and pomalidomide, can be used to induce degradation of a protein of interest that is fused to a short zinc finger (ZF) degron motif. These IMiDs, however, also induce degradation of endogenous neosubstrates, including IKZF1 and IKZF3. To improve degradation selectivity, we took a bump-and-hole approach to design and screen bumped IMiD analogs against 8380 ZF mutants. This yielded a bumped IMiD analog that induces efficient degradation of a mutant ZF degron, while not affecting other cellular proteins, including IKZF1 and IKZF3. In proof-of-concept studies, this system was applied to induce efficient degradation of TRIM28, a disease-relevant protein with no known small molecule binders. We anticipate that this system will make a valuable addition to the current arsenal of degron systems for use in target validation.

2.
Sci Rep ; 6: 35548, 2016 10 14.
Article En | MEDLINE | ID: mdl-27739501

It was recently discovered that vertebrate genomes contain multiple endogenised nucleotide sequences derived from the non-retroviral RNA bornavirus. Strikingly, some of these elements have been evolutionary maintained as open reading frames in host genomes for over 40 million years, suggesting that some endogenised bornavirus-derived elements (EBL) might encode functional proteins. EBLN1 is one such element established through endogenisation of the bornavirus N gene (BDV N). Here, we functionally characterise human EBLN1 as a novel regulator of genome stability. Cells depleted of human EBLN1 accumulate DNA damage both under non-stressed conditions and following exogenously induced DNA damage. EBLN1-depleted cells also exhibit cell cycle abnormalities and defects in microtubule organisation as well as premature centrosome splitting, which we attribute in part, to improper localisation of the nuclear envelope protein TPR. Our data therefore reveal that human EBLN1 possesses important cellular functions within human cells, and suggest that other EBLs present within vertebrate genomes may also possess important cellular functions.


Bornaviridae/metabolism , Cell Cycle/genetics , Genomic Instability , Microtubules/metabolism , Nucleoproteins/metabolism , CDC2 Protein Kinase , Cell Line , Centrosome/metabolism , Cyclin B1/metabolism , DNA Damage , Humans , Nuclear Pore Complex Proteins/metabolism , Nucleoproteins/deficiency , Protein Binding , Proteins/metabolism , Proto-Oncogene Proteins/metabolism
3.
Cell Rep ; 16(10): 2565-2575, 2016 09 06.
Article En | MEDLINE | ID: mdl-27568553

Through an RNAi-based screen for previously uncharacterized regulators of genome stability, we have identified the human protein C5orf45 as an important factor in preventing the accumulation of DNA damage in human cells. Here, we functionally characterize C5orf45 as a binding partner of the MRE11-RAD50-NBS1 (MRN) damage-sensing complex. Hence, we rename C5orf45 as MRNIP for MRN-interacting protein (MRNIP). We find that MRNIP is rapidly recruited to sites of DNA damage. Cells depleted of MRNIP display impaired chromatin loading of the MRN complex, resulting in reduced DNA end resection and defective ATM-mediated DNA damage signaling, a reduced ability to repair DNA breaks, and radiation sensitivity. Finally, we show that MRNIP phosphorylation on serine 115 leads to its nuclear localization, and this modification is required for MRNIP's role in promoting genome stability. Collectively, these data reveal that MRNIP is an important component of the human DNA damage response.


Carrier Proteins/metabolism , DNA Damage , Multiprotein Complexes/metabolism , Nuclear Proteins/metabolism , Ataxia Telangiectasia Mutated Proteins/metabolism , Checkpoint Kinase 2/metabolism , Chromatin/metabolism , DNA Breaks, Double-Stranded/radiation effects , DNA Repair/radiation effects , Endodeoxyribonucleases , HCT116 Cells , HEK293 Cells , HeLa Cells , Humans , Protein Binding/radiation effects , Radiation Tolerance/radiation effects , Radiation, Ionizing , Sequence Homology, Amino Acid , Signal Transduction/radiation effects
4.
Cell Cycle ; 13(21): 3450-9, 2014.
Article En | MEDLINE | ID: mdl-25485589

We previously identified and characterized TELO2 as a human protein that facilitates efficient DNA damage response (DDR) signaling. A subsequent yeast 2-hybrid screen identified LARG; Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (also known as Arhgef12), as a potential novel TELO2 interactor. LARG was previously shown to interact with Pericentrin (PCNT), which, like TELO2, is required for efficient replication stress signaling. Here we confirm interactions between LARG, TELO2 and PCNT and show that a sub-set of LARG co-localizes with PCNT at the centrosome. LARG-deficient cells exhibit replication stress signaling defects as evidenced by; supernumerary centrosomes, reduced replication stress-induced γH2AX and RPA nuclear foci formation, and reduced activation of the replication stress signaling effector kinase Chk1 in response to hydroxyurea. As such, LARG-deficient cells are sensitive to replication stress-inducing agents such as hydroxyurea and mitomycin C. Conversely we also show that depletion of TELO2 and the replication stress signaling kinase ATR leads to RhoA signaling defects. These data therefore reveal a level of crosstalk between the RhoA and DDR signaling pathways. Given that mutations in both ATR and PCNT can give rise to the related primordial dwarfism disorders of Seckel Syndrome and Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) respectively, which both exhibit defects in ATR-dependent checkpoint signaling, these data also raise the possibility that mutations in LARG or disruption to RhoA signaling may be contributory factors to the etiology of a sub-set of primordial dwarfism disorders.


Rho Guanine Nucleotide Exchange Factors/metabolism , Signal Transduction , Antigens/metabolism , Ataxia Telangiectasia Mutated Proteins/metabolism , Cell Survival/drug effects , Centrosome/metabolism , Checkpoint Kinase 1 , DNA Repair , DNA Replication/drug effects , HCT116 Cells , HEK293 Cells , HeLa Cells , Humans , Hydroxyurea/pharmacology , Mitomycin/pharmacology , Phosphorylation/drug effects , Protein Kinases/metabolism , RNA, Small Interfering/metabolism , Rho Guanine Nucleotide Exchange Factors/antagonists & inhibitors , Rho Guanine Nucleotide Exchange Factors/genetics , Telomere-Binding Proteins/antagonists & inhibitors , Telomere-Binding Proteins/genetics , Telomere-Binding Proteins/metabolism , rhoA GTP-Binding Protein/metabolism
5.
Oncotarget ; 5(15): 6414-24, 2014 Aug 15.
Article En | MEDLINE | ID: mdl-25071006

Brain tumours kill more children and adults under 40 than any other cancer. Around half of primary brain tumours are glioblastoma multiforme (GBMs) where treatment remains a significant challenge, where survival rates have improved little over the last 40 years, thus highlighting an unmet need for the identification/development of novel therapeutic targets and agents to improve GBM treatment. Using archived and fresh glioma tissue, we show that in contrast to normal brain or benign schwannomas GBMs exhibit re-expression of FANCD2, a key protein of the Fanconi Anaemia (FA) DNA repair pathway, and possess an active FA pathway. Importantly, FANCD2 expression levels are strongly associated with tumour grade, revealing a potential exploitable therapeutic window to allow inhibition of the FA pathway in tumour cells, whilst sparing normal brain tissue. Using several small molecule inhibitors of the FA pathway in combination with isogenic FA-proficient/deficient glioma cell lines as well as primary GBM cultures, we demonstrate that inhibition of the FA pathway sensitises gliomas to the chemotherapeutic agents Temozolomide and Carmustine. Our findings therefore provide a strong rationale for the development of novel and potent inhibitors of the FA pathway to improve the treatment of GBMs, which may ultimately impact on patient outcome.


Antineoplastic Agents, Alkylating/pharmacology , Brain Neoplasms/drug therapy , Brain Neoplasms/metabolism , Fanconi Anemia Complementation Group D2 Protein/biosynthesis , Fanconi Anemia/metabolism , Glioma/drug therapy , Glioma/metabolism , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Carmustine/pharmacology , Cell Line, Tumor , Curcumin/metabolism , Dacarbazine/analogs & derivatives , Dacarbazine/pharmacology , Fanconi Anemia/genetics , Fanconi Anemia/pathology , Glioma/genetics , Glioma/pathology , Humans , Neoplasm Grading , Temozolomide
6.
J Cell Sci ; 127(Pt 13): 2910-9, 2014 Jul 01.
Article En | MEDLINE | ID: mdl-24816561

Here, we identify coiled-coil domain-containing protein 13 (Ccdc13) in a genome-wide RNA interference screen for regulators of genome stability. We establish that Ccdc13 is a newly identified centriolar satellite protein that interacts with PCM1, Cep290 and pericentrin and prevents the accumulation of DNA damage during mitotic transit. Depletion of Ccdc13 results in the loss of microtubule organisation in a manner similar to PCM1 and Cep290 depletion, although Ccdc13 is not required for satellite integrity. We show that microtubule regrowth is enhanced in Ccdc13-depleted cells, but slowed in cells that overexpress Ccdc13. Furthermore, in serum-starved cells, Ccdc13 localises to the basal body, is required for primary cilia formation and promotes the localisation of the ciliopathy protein BBS4 to both centriolar satellites and cilia. These data highlight the emerging link between DNA damage response factors, centriolar and peri-centriolar satellites and cilia-associated proteins and implicate Ccdc13 as a centriolar satellite protein that functions to promote both genome stability and cilia formation.


Cell Cycle Proteins/physiology , Centrioles/metabolism , Cilia/metabolism , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Genomic Instability , HCT116 Cells , HEK293 Cells , HeLa Cells , Humans , Transfection
7.
J Cell Sci ; 125(Pt 20): 4770-9, 2012 Oct 15.
Article En | MEDLINE | ID: mdl-22797915

The centrosome acts as a centre for microtubule organisation and plays crucial roles in cell polarity, migration, growth and division. Cep131 has recently been described as a basal body component essential for cilium formation, but its function in non-ciliogenic cells is unknown. We identified human Cep131 (also known as AZI1) in a screen for regulators of genome stability. We show that centrosomal localisation of Cep131 is cell-cycle-regulated and requires both an intact microtubule network and a functional dynein-dynactin transport system. Cep131 is recruited to centriolar satellites by PCM1, and localised to the centriolar core region by both pericentrin and Cep290. Depletion of Cep131 results in a reduction in proliferation rate, centriole amplification, an increased frequency of multipolar mitosis, chromosomal instability and an increase in post-mitotic DNA damage. These data therefore highlight the importance of human Cep131 for maintaining genomic integrity.


Cell Cycle Proteins , Centrioles , Centrosome , Genomic Instability , Microtubule Proteins , Antigens, Neoplasm/metabolism , Autoantigens/metabolism , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cell Line , Centrioles/genetics , Centrioles/ultrastructure , Centrosome/metabolism , Centrosome/ultrastructure , Chromosomal Instability , Cytoskeletal Proteins , Dynactin Complex , Dyneins/metabolism , Humans , Microtubule Proteins/genetics , Microtubule Proteins/metabolism , Microtubule-Associated Proteins/metabolism , Mitosis/genetics , Neoplasm Proteins/metabolism
...